DiaMedica Q2 loss $10.1M; PE trial shows 29.1 mmHg SBP drop

DiaMedica Therapeutics Inc.

Net loss $10.1M in Q2 2026 vs $7.7M Q2 2025; six-month loss $20.2M vs $15.4M.
Cash $43.5M at June 30, 2026 vs $59.9M at Dec 31, 2025; runway through 2027.
Phase 2 PE Part 1a: DM199 reduced SBP 29.1 mmHg (p<0.001) from 169.3 mmHg baseline; DBP 17.0 mmHg.
FGR Phase 2 first cohort of 6 patients (5 µg/kg) fully enrolled; topline results due September.
ReMEDy2 AIS trial enrollment >85% of 200 patients; interim analysis expected Q1 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.